Inovio Pharmaceuticals, Inc.
INO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $49,704 | $135,703 | $372,251 | $12,851,611 |
| - Cash | $65,813 | $14,311 | $46,329 | $71,144 |
| + Debt | $11,865 | $30,209 | $32,074 | $33,023 |
| Enterprise Value | -$4,244 | $151,602 | $357,996 | $12,813,491 |
| Revenue | $218 | $832 | $10,262 | $1,775 |
| % Growth | -73.8% | -91.9% | 478.2% | – |
| Gross Profit | $218 | $832 | $10,262 | $1,775 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$103,946 | -$130,391 | -$270,903 | -$296,557 |
| % Margin | -47,735.2% | -15,671.8% | -2,639.8% | -16,709.7% |
| Net Income | -$107,254 | -$135,117 | -$279,818 | -$303,659 |
| % Margin | -49,254.3% | -16,239.9% | -2,726.7% | -17,109.9% |
| EPS Diluted | -3.95 | -6.09 | -14.07 | -1.42 |
| % Growth | 35.1% | 56.7% | -890.8% | – |
| Operating Cash Flow | -$104,077 | -$124,366 | -$216,215 | -$215,709 |
| Capital Expenditures | -$488 | -$321 | -$969 | -$1,231 |
| Free Cash Flow | -$104,564 | -$124,686 | -$217,185 | -$216,940 |